{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:21Z","timestamp":1791357381523,"version":"4.3.1"},"reference-count":233,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["NeuroToxicology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.neuro.2019.08.002","type":"journal-article","created":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T09:39:36Z","timestamp":1565516376000},"page":"282-298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":150,"special_numbering":"C","title":["Cannabidiol (CBD) use in psychiatric disorders: A systematic review"],"prefix":"10.1016","volume":"74","author":[{"given":"Stefania","family":"Bonaccorso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Ricciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Zangani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Chiappini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Schifano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuro.2019.08.002_bib0005","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/npp.2013.51","article-title":"Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory","volume":"38","author":"Abush","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuro.2019.08.002_bib0010","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1021\/ja01858a058","article-title":"Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp","volume":"62","author":"Adams","year":"1940","journal-title":"J. Am. Chem. Soc."},{"issue":"3","key":"10.1016\/j.neuro.2019.08.002_bib0015","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamapsychiatry.2013.3947","article-title":"Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial","volume":"71","author":"Allsop","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neuro.2019.08.002_bib0020","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"32","key":"10.1016\/j.neuro.2019.08.002_bib0025","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.2174\/138161212802884726","article-title":"The yin and yang of cannabis-induced psychosis: the actions of \u0394(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia","volume":"18","author":"Arnold","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuro.2019.08.002_bib0030","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3233\/JAD-130137","article-title":"CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in A aPP\/PS1 mice","volume":"35","author":"Aso","year":"2013","journal-title":"J. Alzheimer Dis."},{"key":"10.1016\/j.neuro.2019.08.002_bib0035","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3233\/JAD-160533","article-title":"Delineating the efficacy of a cannabis-based medicine at advanced stages of dementia in a murine model","volume":"54","author":"Aso","year":"2016","journal-title":"J. Alzheimer Dis."},{"issue":"2","key":"10.1016\/j.neuro.2019.08.002_bib0040","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3233\/JAD-150913","article-title":"Cannabinoid receptor 2 participates in Amyloid-\u03b2 processing in a mouse model of alzheimer\u2019s disease but plays a minor role in the therapeutic properties of a cannabis-based medicine","volume":"51","author":"Aso","year":"2016","journal-title":"J. Alzheimers Dis."},{"issue":"7","key":"10.1016\/j.neuro.2019.08.002_bib0045","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/j.1476-5381.2010.01179.x","article-title":"Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice","volume":"162","author":"Avraham","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuro.2019.08.002_bib0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","article-title":"Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers","volume":"172","author":"Sparenborg","year":"2017","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.neuro.2019.08.002_bib0055","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11920-017-0775-9","article-title":"Cannabinoids, and sleep: a review of the literature","volume":"19","author":"Babson","year":"2017","journal-title":"Curr. Psychiatry Rep."},{"issue":"1\u20133","key":"10.1016\/j.neuro.2019.08.002_bib0060","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejphar.2012.09.053","article-title":"Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis","volume":"697","author":"Barichello","year":"2012","journal-title":"Eur. J. Pharmacol."},{"issue":"January","key":"10.1016\/j.neuro.2019.08.002_bib0065","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3389\/fphar.2018.01521","article-title":"Oral cannabidiol use in children with autism Spectrum disorder to treat related symptoms and Co-morbidities","volume":"9","author":"Barchel","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuro.2019.08.002_bib0070","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/npp.2009.184","article-title":"Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology","volume":"35","author":"Bhattacharyya","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/archgenpsychiatry.2011.161","article-title":"Induction of psychosis by \u03949-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing","volume":"69","author":"Bhattacharyya","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuro.2019.08.002_bib0080","article-title":"Effect of cannabidiol on paranoid ideation in a virtual reality environment in individuals at Ultra High Risk of Psychosis","author":"Bhattacharyya","year":"2016","journal-title":"Early Interv. Psychiatry"},{"issue":"11","key":"10.1016\/j.neuro.2019.08.002_bib0085","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2018.2309","article-title":"Effect of cannabidiol on medial temporal, Midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial","volume":"75","author":"Bhattacharyya","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.neuro.2019.08.002_bib0090","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1093\/schbul\/sby014.067","article-title":"Effect of cannabidiol on symptoms, distress and neurophysiological abnormalities in clinical high-risk for psychosis patients: a placebo-controlled study","volume":"44","author":"Bhattacharyya","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuro.2019.08.002_bib0095","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.addbeh.2015.06.032","article-title":"Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users","volume":"50","author":"Belendiuk","year":"2015","journal-title":"Addict. Behav."},{"key":"10.1016\/j.neuro.2019.08.002_bib0100","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.phrs.2016.07.024","article-title":"The endocannabinoid system and Post Traumatic Stress Disorder (PTSD): from preclinical findings to innovative therapeutic approaches in clinical settings","volume":"111","author":"Berardi","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.neuro.2019.08.002_bib0105","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.neuro.2019.08.002_bib0110","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/157488611798280924","article-title":"Safety and side effects of cannabidiol, a Cannabis sativa constituent","volume":"6","author":"Bergamaschi","year":"2011","journal-title":"Curr. Drug Saf."},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0115","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12888-018-1682-2","article-title":"Agonist Replacement for Cannabis dependence (ARCD) study group. Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol","volume":"18","author":"Bhardwaj","year":"2018","journal-title":"BMC Psychiatry"},{"issue":"4","key":"10.1016\/j.neuro.2019.08.002_bib0120","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuro.2019.08.002_bib0125","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.euroneuro.2008.07.001","article-title":"Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats","volume":"18","author":"Bitencourt","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuro.2019.08.002_bib0130","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3389\/fnins.2018.00502","article-title":"Cannabidiol as a therapeutic alternative for post-traumatic stress disorder: from bench research to confirmation in human trials","volume":"12","author":"Bitencourt","year":"2018","journal-title":"Front. Neurosci."},{"issue":"4","key":"10.1016\/j.neuro.2019.08.002_bib0135","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a potential treatment for anxiety disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0140","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/npp.2017.209","article-title":"Clinical and preclinical evidence for functional interactions of cannabidiol and \u03949-Tetrahydrocannabinol","volume":"43","author":"Boggs","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.neuro.2019.08.002_bib0145","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","article-title":"The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia: a randomized placebo-controlled trial","volume":"235","author":"Boggs","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuro.2019.08.002_bib0150","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.phrs.2019.01.009","article-title":"Blood-brain barrier disturbances in diabetes-associated dementia: therapeutic potential for cannabinoids","volume":"141","author":"Brook","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.neuro.2019.08.002_bib0155","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00213-008-1168-x","article-title":"Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats","volume":"199","author":"Campos","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuro.2019.08.002_bib0160","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","article-title":"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders","volume":"367","author":"Campos","year":"2012","journal-title":"Philos. Trans. Biol. Sci."},{"issue":"6","key":"10.1016\/j.neuro.2019.08.002_bib0165","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1017\/S1461145712001502","article-title":"The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system","volume":"16","author":"Campos","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuro.2019.08.002_bib0170","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.phrs.2016.01.033","article-title":"Cannabidiol, neuroprotection and neuropsychiatric disorders","volume":"112","author":"Campos","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"8","key":"10.1016\/j.neuro.2019.08.002_bib0175","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3389\/fphar.2017.00269","article-title":"Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders","volume":"23","author":"Campos","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"S1","key":"10.1016\/j.neuro.2019.08.002_bib0180","doi-asserted-by":"crossref","first-page":"417S","DOI":"10.1002\/j.1552-4604.1981.tb02622.x","article-title":"Hypnotic and antiepileptic effects of cannabidiol","volume":"21","author":"Carlini","year":"1981","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.neuro.2019.08.002_bib0185","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.neubiorev.2011.04.007","article-title":"Cannabis use in young people: the risk for schizophrenia","volume":"35","author":"Casadio","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"3","key":"10.1016\/j.neuro.2019.08.002_bib0190","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3233\/JAD-130050","article-title":"Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of Tauopathy","volume":"35","author":"Casarejos","year":"2013","journal-title":"J. Alzheimer Dis."},{"issue":"2","key":"10.1016\/j.neuro.2019.08.002_bib0195","doi-asserted-by":"crossref","first-page":"140","DOI":"10.20882\/adicciones.858","article-title":"Psychoactive constituents of cannabis and their clinical implications: a systematic review","volume":"30","author":"Casajuana K\u00f6guel","year":"2018","journal-title":"Adicciones"},{"issue":"4","key":"10.1016\/j.neuro.2019.08.002_bib0200","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/FBP.0b013e32833b33c5","article-title":"Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors","volume":"21","author":"Casarotto","year":"2010","journal-title":"Behav. Pharmacol."},{"issue":"11","key":"10.1016\/j.neuro.2019.08.002_bib0205","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0269881114550355","article-title":"Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: an exploratory double-blind trial","volume":"28","author":"Chagas","year":"2014","journal-title":"J. Psychopharmacol. (Oxford)"},{"issue":"4","key":"10.1016\/j.neuro.2019.08.002_bib0210","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3233\/JAD-140921","article-title":"Long-term cannabidiol treatment prevents the development of social recognition memory deficits in alzheimer\u2019s disease transgenic mice","volume":"42","author":"Cheng","year":"2014","journal-title":"J. Alzheimer Dis."},{"issue":"15","key":"10.1016\/j.neuro.2019.08.002_bib0215","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1007\/s00213-014-3478-5","article-title":"Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe\/PS1\u0394E9 mice","volume":"231","author":"Cheng","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuro.2019.08.002_bib0220","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3389\/fpsyt.2019.00063","article-title":"The endocannabinoid system and cannabidiol\u2019s promise for the treatment of substance use disorder","volume":"10","author":"Chye","year":"2019","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neuro.2019.08.002_bib0225","series-title":"NCT02759185. Study of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD","author":"Clinical Trials.gov","year":"2016"},{"key":"10.1016\/j.neuro.2019.08.002_bib0230","series-title":"NCT03310593. Cannabidiol as an Adjunctive Treatment for Bipolar Depression","author":"Clinical Trials.gov","year":"2017"},{"key":"10.1016\/j.neuro.2019.08.002_bib0235","series-title":"NCT03248167. Cannabidiol As a Treatment for AUD Comorbid With PTSD","author":"Clinical Trials.gov","year":"2017"},{"key":"10.1016\/j.neuro.2019.08.002_bib0240","series-title":"NCT03549819. Cannabidiol for the Treatment of Anxiety Disorders: an 8-Week Pilot Study","author":"Clinical Trials.gov","year":"2018"},{"key":"10.1016\/j.neuro.2019.08.002_bib0245","series-title":"NCT03518801. Cannabidiol and Prolonged Exposure","author":"Clinical Trials.gov","year":"2018"},{"issue":"2","key":"10.1016\/j.neuro.2019.08.002_bib0250","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s40429-017-0142-2","article-title":"Does Cannabis composition matter? Differential effects of Delta-9-tetrahydrocannabinol and cannabidiol on human cognition","volume":"4","author":"Colizzi","year":"2017","journal-title":"Curr. Addict. Rep."},{"key":"10.1016\/j.neuro.2019.08.002_bib0255","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","article-title":"Controlled clinical trial of cannabidiol in huntington\u2019s disease","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0260","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/can.2018.0006","article-title":"A cross-sectional study of cannabidiol users","volume":"3","author":"Corroon","year":"2018","journal-title":"Cannabis Cannabinoid Res."},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0265","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0269881110379283","article-title":"Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report","volume":"25","author":"Crippa","year":"2011","journal-title":"J. Psychopharmacol. (Oxford)"},{"issue":"2","key":"10.1016\/j.neuro.2019.08.002_bib0270","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/jcpt.12018","article-title":"Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report","volume":"38","author":"Crippa","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"issue":"8","key":"10.1016\/j.neuro.2019.08.002_bib0275","doi-asserted-by":"crossref","first-page":"970","DOI":"10.2174\/1871527314666150909113930","article-title":"Cannabidiol and sodium nitroprusside: two novel neuromodulatory pharmacological interventions to treat and prevent psychosis","volume":"14","author":"Crippa","year":"2015","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.neuro.2019.08.002_bib0280","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.3389\/fimmu.2018.02009","article-title":"Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age","volume":"9","author":"Crippa","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0285","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41398-018-0232-5","article-title":"Antiapoptotic effects of cannabidiol in an experimental model of cognitive decline induced by brain iron overload","volume":"8","author":"da Silva","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuro.2019.08.002_bib0290","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00213-012-2955-y","article-title":"Cannabidiol enhances consolidation of explicit fear extinction in humans","volume":"226","author":"Das","year":"2013","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.neuro.2019.08.002_bib0295","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00213-011-2415-0","volume":"219","author":"Deiana","year":"2012","journal-title":"Psychopharmacology"},{"issue":"Supl1","key":"10.1016\/j.neuro.2019.08.002_bib0300","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/S1516-4446(12)70057-0","article-title":"Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug","volume":"34","author":"de Mello Schier","year":"2012","journal-title":"Rev. Bras. Psiquiatr."},{"issue":"5090","key":"10.1016\/j.neuro.2019.08.002_bib0305","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.neuro.2019.08.002_bib0310","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S2215-0366(14)00117-5","article-title":"Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study","volume":"2","author":"Di Forti","year":"2015","journal-title":"Lancet Psychiatry"},{"issue":"March","key":"10.1016\/j.neuro.2019.08.002_bib0315","article-title":"The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study","author":"Di Forti","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.neuro.2019.08.002_bib0320","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/medicines5030086","article-title":"The role of Cannabis within an emerging perspective on schizophrenia","volume":"5","author":"Diviant","year":"2018","journal-title":"Medicines"},{"issue":"2","key":"10.1016\/j.neuro.2019.08.002_bib0325","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020129","article-title":"Prospects for the use of cannabinoids in oncology and palliative care practice: a review of the evidence","volume":"11","author":"Dzier\u017canowski","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.neuro.2019.08.002_bib0330","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.pbb.2010.03.004","article-title":"Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L","volume":"95","author":"El-Alfy","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"14","key":"10.1016\/j.neuro.2019.08.002_bib0335","doi-asserted-by":"crossref","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","article-title":"Fatty acid-binding proteins (FABPs) are intracellular carriers for \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD)","volume":"290","author":"Elmes","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"December","key":"10.1016\/j.neuro.2019.08.002_bib0340","article-title":"Cannabidiol in the treatment of post-traumatic stress disorder: a case series","author":"Elms","year":"2018","journal-title":"J. Altern. Complement. Med."},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0345","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0269881112460109","article-title":"Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment","volume":"27","author":"Englund","year":"2013","journal-title":"J. Psychopharmacol. (Oxford)"},{"key":"10.1016\/j.neuro.2019.08.002_bib0350","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1210\/en.2010-0285","article-title":"Fast feedback inhibition of the HPA axis by glucocorticoids is mediated by endocannabinoid signaling","volume":"151","author":"Evanson","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuro.2019.08.002_bib0355","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jpsychires.2016.05.013","article-title":"Could cannabidiol be used as an alternative to antipsychotics?","volume":"80","author":"Fakhoury","year":"2016","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0360","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s12035-016-9697-5","article-title":"Role of the endocannabinoid system in the pathophysiology of schizophrenia","volume":"54","author":"Fakhoury","year":"2017","journal-title":"Mol. Neurobiol."},{"issue":"4","key":"10.1016\/j.neuro.2019.08.002_bib0365","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00213-011-2449-3","article-title":"Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders","volume":"219","author":"Fagherazzi","year":"2012","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0370","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00213-012-2697-x","article-title":"Cannabinol and cannabidiol exert opposing effects on rat feeding patterns","volume":"223","author":"Farrimond","year":"2012","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.neuro.2019.08.002_bib0375","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/phar.1780","article-title":"Current status and prospects for cannabidiol preparations as new therapeutic agents","volume":"36","author":"Fasinu","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.neuro.2019.08.002_bib0380","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-244X-5-17","article-title":"Two cases of \u201ccannabis acute psychosis\u201d following the administration of oral cannabis","volume":"5","author":"Favrat","year":"2005","journal-title":"BMC Psychiatry"},{"issue":"2","key":"10.1016\/j.neuro.2019.08.002_bib0385","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2125.2012.04341.x","article-title":"Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?","volume":"75","author":"Fern\u00e1ndez-Ruiz","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"Suppl. 2","key":"10.1016\/j.neuro.2019.08.002_bib0390","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1016\/j.rbp.2012.07.003","article-title":"The endocannabinoid system and its role in schizophrenia: a systematic review of the literature","volume":"34","author":"Ferretjans","year":"2012","journal-title":"Br. J. Psychiatr."},{"key":"10.1016\/j.neuro.2019.08.002_bib0395","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.euroneuro.2013.10.012","article-title":"Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: involvement of 5HT1A receptors and previous stressful experience","volume":"24","author":"Fogaca","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuro.2019.08.002_bib0400","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neuropharm.2018.03.001","article-title":"The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: role of neurogenesis and dendritic remodeling","volume":"135","author":"Foga\u00e7a","year":"2018","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0405","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archgenpsychiatry.2008.519","article-title":"Distinct effects of \u03949-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing","volume":"66","author":"Fusar-Poli","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuro.2019.08.002_bib0410","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jad.2014.09.016","article-title":"Cannabis use and mania symptoms: a systematic review and meta-analysis","volume":"171","author":"Broome","year":"2015","journal-title":"J. Affect. Disord."},{"issue":"11","key":"10.1016\/j.neuro.2019.08.002_bib0415","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","article-title":"Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms","volume":"29","author":"Giuffrida","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.neuro.2019.08.002_bib0420","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.schres.2015.01.015","article-title":"Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol","volume":"164","author":"Gomes","year":"2015","journal-title":"Schizophr. Res."},{"issue":"10","key":"10.1016\/j.neuro.2019.08.002_bib0425","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/s41386-018-0050-8","article-title":"Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle","volume":"43","author":"Gonzalez-Cuevas","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.neuro.2019.08.002_bib0430","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","article-title":"Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms","volume":"29","author":"Giuffrida","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuro.2019.08.002_bib0435","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1523\/JNEUROSCI.2737-14.2015","article-title":"Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety","volume":"35","author":"Gray","year":"2015","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0440","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/02791072.2013.873843","article-title":"PTSD symptom reports of patients evaluated for the New Mexico medical Cannabis program","volume":"46","author":"Greer","year":"2014","journal-title":"J. Psychoactive Drugs"},{"issue":"2\u20133","key":"10.1016\/j.neuro.2019.08.002_bib0445","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.schres.2016.06.022","article-title":"Does cannabidiol have a role in the treatment of schizophrenia?","volume":"176","author":"Gururajan","year":"2016","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0450","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/schbul\/sbx105","article-title":"The potential of Cannabidiol Treatment for cannabis users with Recent-Onset Psychosis","volume":"44","author":"Hahn","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.neuro.2019.08.002_bib0455","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/j.2051-5545.2008.tb00158.x","article-title":"Cannabis use and the risk of developing a psychotic disorder","volume":"7","author":"Hall","year":"2008","journal-title":"World Psychiatry"},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0460","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1590\/S1516-44462010000100011","article-title":"Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)","volume":"32","author":"Hallak","year":"2010","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0465","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.pnpbp.2010.11.002","article-title":"The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects","volume":"135","author":"Hallak","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuro.2019.08.002_bib0470","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1038\/tp.2012.90","article-title":"Failure to extinguish fear and genetic variability in the human cannabinoid receptor 1","volume":"2","author":"Heitland","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuro.2019.08.002_bib0475","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00008877-200509000-00006","article-title":"Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?","volume":"16","author":"Hill","year":"2005","journal-title":"Behav. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0480","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.pharmthera.2011.09.002","article-title":"Phytocannabinoids as novel therapeutic agents in CNS disorders","volume":"133","author":"Hill","year":"2012","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0485","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/npp.2017.162","article-title":"Integrating endocannabinoid signaling and cannabinoids into the biology and treatment of posttraumatic stress disorder","volume":"43","author":"Hill","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.neuro.2019.08.002_bib0490","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.euroneuro.2014.11.014","article-title":"Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double- blind, placebo-controlled study in cannabis users","volume":"25","author":"Gardener","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"9","key":"10.1016\/j.neuro.2019.08.002_bib0495","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1111\/add.14243","article-title":"Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal","volume":"113","author":"Hindocha","year":"2018","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.neuro.2019.08.002_bib0500","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/ph11020055","article-title":"Endocannabinoids in body weight control","volume":"11","author":"Horn","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0505","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.neuropharm.2011.08.013","article-title":"Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats","volume":"62","author":"Hsiao","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuro.2019.08.002_bib0510","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s13311-015-0373-7","article-title":"Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage","volume":"12","author":"Hurd","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuro.2019.08.002_bib0515","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2019.18101191","article-title":"Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial","author":"Hurd","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"Winter (1)","key":"10.1016\/j.neuro.2019.08.002_bib0520","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1755-5949.2008.00065.x","article-title":"Cannabidiol: a promising drug for neurodegenerative disorders?","volume":"15","author":"Iuvone","year":"2009","journal-title":"CNS Neurosci. Ther."},{"issue":"8","key":"10.1016\/j.neuro.2019.08.002_bib0525","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.3390\/ph3082647","article-title":"The potential role of cannabinoids in modulating serotonergic signaling by their influence on tryptophan metabolism","volume":"3","author":"Jenny","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.neuro.2019.08.002_bib0530","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3389\/fphar.2016.00454","article-title":"Cannabidiol regulation of learned fear: implications for treating anxiety-related disorders","volume":"7","author":"Jurkus","year":"2016","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0535","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1176\/appi.ajp.160.1.13","article-title":"Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia","volume":"160","author":"Kapur","year":"2003","journal-title":"Am. J. Psychiatry"},{"issue":"2 and 3-Spec Issue","key":"10.1016\/j.neuro.2019.08.002_bib0540","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/FBP.0000000000000247","article-title":"The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer\u2019s disease","volume":"28","author":"Karl","year":"2017","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuro.2019.08.002_bib0545","first-page":"1","article-title":"Is there a role for cannabidiol in psychiatry?","volume":"20","author":"Khoury","year":"2017","journal-title":"World J. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.neuro.2019.08.002_bib0550","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1515\/jbcpp-2015-0058","article-title":"Targeting the endocannabinoid system to treat anxiety-related disorders","volume":"27","author":"Korem","year":"2016","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuro.2019.08.002_bib0555","doi-asserted-by":"crossref","first-page":"309","DOI":"10.31887\/DCNS.2017.19.3\/glafaye","article-title":"Cannabis, cannabinoids and health","volume":"19","author":"Lafaye","year":"2017","journal-title":"Dialogues Clin. Neurosci."},{"issue":"October","key":"10.1016\/j.neuro.2019.08.002_bib0560","article-title":"Cannabidiol affects circadian clock core complex and its regulation in microglia cells","author":"Lafaye","year":"2018","journal-title":"Addict. Biol."},{"issue":"October (19)","key":"10.1016\/j.neuro.2019.08.002_bib0565","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1111\/bph.13724","article-title":"Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders","volume":"174","author":"Lee","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"1\u20133","key":"10.1016\/j.neuro.2019.08.002_bib0570","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2007.04.025","article-title":"Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use","volume":"94","author":"Leweke","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuro.2019.08.002_bib0575","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"issue":"8, Supp 1","key":"10.1016\/j.neuro.2019.08.002_bib0580","first-page":"63S","article-title":"Cannabidiol as a new type of an antipsychotic: results from a placebo-controlled clinical trial","volume":"71","author":"Leweke","year":"2012","journal-title":"Biol. Psychiatry"},{"issue":"Suppl. S1","key":"10.1016\/j.neuro.2019.08.002_bib0585","article-title":"Enhancing recovery in early schizophrenia - A controlled clinical trial investigating cannabidiol CR versus. Placebo as an add-on to antipsychotic treatment","volume":"8","author":"Leweke","year":"2014","journal-title":"Early Interv. Psychiatry"},{"key":"10.1016\/j.neuro.2019.08.002_bib0590","first-page":"14","article-title":"A homeostatic role for the endocannabinoid system in schizophrenia","volume":"17","author":"Leweke","year":"2014","journal-title":"IJNP"},{"issue":"5","key":"10.1016\/j.neuro.2019.08.002_bib0595","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1055\/s-0038-1651941","article-title":"Cannabidiol zur Verbesserung der Genesung in fr\u00fchen Stadien einer Schizophrenie. Eine randomisierte, kontrollierte klinische Pr\u00fcfungder adjuvanten Gabe zur individuellen antipsychotischen Behandlung","volume":"37","author":"Leweke","year":"2018","journal-title":"Nervenheilkunde"},{"issue":"4","key":"10.1016\/j.neuro.2019.08.002_bib0600","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1152\/physrev.00002.2016","article-title":"From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology","volume":"96","author":"Ligresti","year":"2016","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.neuro.2019.08.002_bib0605","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.1016\/S0924-977X(16)31310-4","article-title":"Lack of cannabidiol effects on sleep-wake cycle in healthy patients","volume":"26","author":"Linares","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuro.2019.08.002_bib0610","doi-asserted-by":"crossref","first-page":"S617","DOI":"10.1016\/S0924-977X(16)31702-3","article-title":"Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test","volume":"26","author":"Linares","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuro.2019.08.002_bib0615","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3389\/fphar.2018.00315","article-title":"No acute effects of cannabidiol on the sleep-wake cycle of healthy subjects: a randomized, double-blind, placebo-controlled, crossover study","volume":"9","author":"Linares","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuro.2019.08.002_bib0620","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2015.12.017","article-title":"Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT\/glutamate neurotransmission: role of 5-HT1A receptors","volume":"103","author":"Linge","year":"2016","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0625","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00213-018-5127-x","article-title":"Tempering aversive\/traumatic memories with cannabinoids: a review of evidence from animal and human studies","volume":"236","author":"Lisboa","year":"2019","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.neuro.2019.08.002_bib0630","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","article-title":"A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington\u2019s disease","volume":"263","author":"L\u00f3pez-Send\u00f3n Moreno","year":"2016","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.neuro.2019.08.002_bib0635","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","article-title":"An introduction to the endogenous cannabinoid system","volume":"79","author":"Lu","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.neuro.2019.08.002_bib0640","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1017\/S2045796018000239","article-title":"Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview","volume":"27","author":"Mandolini","year":"2018","journal-title":"Epidemiol. Psychiatr. Sci."},{"issue":"5","key":"10.1016\/j.neuro.2019.08.002_bib0645","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2174\/1871527316666170413114210","article-title":"Neurological aspects of medical use of cannabidiol","volume":"16","author":"Mannucci","year":"2017","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.neuro.2019.08.002_bib0650","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3389\/fnbeh.2011.00063","article-title":"Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects","volume":"5","author":"Marco","year":"2011","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuro.2019.08.002_bib0655","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbr.2015.02.023","article-title":"Effects of intra-infralimbic prefrontal cortex injections of cannabidiol in the modulation of emotional behaviors in rats: contribution of 5HT\u2081A receptors and stressful experiences","volume":"286","author":"Marinho","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuro.2019.08.002_bib0660","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00213-001-0946-5","article-title":"Involvement of CB1 cannabinoid receptors in emotional behaviour","volume":"159","author":"Martin","year":"2002","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.neuro.2019.08.002_bib0665","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1124\/mol.111.071290","article-title":"Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to alzheimer\u2019s disease","volume":"79","author":"Mart\u00edn-Moreno","year":"2011","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuro.2019.08.002_bib0670","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial","volume":"175","author":"Robson","year":"2018","journal-title":"Am. J. Psychiatry"},{"issue":"Supp 1","key":"10.1016\/j.neuro.2019.08.002_bib0675","first-page":"S27","article-title":"A randomized controlled trial of cannabidiol in schizophrenia","volume":"44","author":"Robson","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"3945","key":"10.1016\/j.neuro.2019.08.002_bib0680","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1126\/science.169.3945.611","article-title":"Chemical basis of hashish activity","volume":"169","author":"Mechoulam","year":"1970","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0685","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2012.12.002","article-title":"Endocannabinoid system and mood disorders: priming a target for new therapies","volume":"138","author":"Micale","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuro.2019.08.002_bib0690","article-title":"Measuring disturbance of the endocannabinoid system in psychosis: a systematic review and meta-analysis","author":"Cipriani","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"10.1016\/j.neuro.2019.08.002_bib0695","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"9584","key":"10.1016\/j.neuro.2019.08.002_bib0700","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(07)61162-3","article-title":"Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review","volume":"370","author":"Moore","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.neuro.2019.08.002_bib0705","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1590\/S1516-44462009000200012","article-title":"The psychiatric side-effects of rimonabant","volume":"31","author":"Moreira","year":"2009","journal-title":"Rev. Bras. Psiquiatr."},{"issue":"2","key":"10.1016\/j.neuro.2019.08.002_bib0710","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1017\/S0033291711001322","article-title":"Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being","volume":"42","author":"Morgan","year":"2012","journal-title":"Psychol. Med. (Paris)"},{"issue":"4","key":"10.1016\/j.neuro.2019.08.002_bib0715","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1192\/bjp.bp.107.046649","article-title":"Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis","volume":"192","author":"Morgan","year":"2008","journal-title":"Br. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.neuro.2019.08.002_bib0720","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/npp.2010.58","article-title":"Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis","volume":"35","author":"Morgan","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.neuro.2019.08.002_bib0725","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1192\/bjp.bp.110.077503","article-title":"Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study","volume":"197","author":"Morgan","year":"2010","journal-title":"Br. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.neuro.2019.08.002_bib0730","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","article-title":"Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings","volume":"38","author":"Morgan","year":"2013","journal-title":"Addict. Behav."},{"key":"10.1016\/j.neuro.2019.08.002_bib0735","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pnpbp.2016.11.005","article-title":"Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia","volume":"75","author":"Mori","year":"2017","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"July (4)","key":"10.1016\/j.neuro.2019.08.002_bib0740","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/schbul\/sbp049","article-title":"From real-world events to psychosis: the emerging neuropharmacology of delusions","volume":"35","author":"Morrison","year":"2009","journal-title":"Schizophr. Bull."},{"issue":"February","key":"10.1016\/j.neuro.2019.08.002_bib0745","article-title":"Cannabinoids: the lows and the highs of chemotherapy-induced nausea and vomiting","author":"Mortimer","year":"2019","journal-title":"Future Oncol."},{"issue":"18","key":"10.1016\/j.neuro.2019.08.002_bib0750","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1016\/j.febslet.2006.04.102","article-title":"Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats","volume":"580","author":"Murillo-Rodr\u00edguez","year":"2006","journal-title":"FEBS"},{"issue":"11\u201312","key":"10.1016\/j.neuro.2019.08.002_bib0755","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.lfs.2011.01.013","article-title":"Effects on sleep and dopamine levels of microdialysis perfusion of cannabidiol into the lateral hypothalamus of rats","volume":"88","author":"Murillo-Rodr\u00edguez","year":"2011","journal-title":"Life Sci."},{"key":"10.1016\/j.neuro.2019.08.002_bib0760","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.neuroscience.2016.10.011","article-title":"Revealing the role of the endocannabinoid system modulators, SR141716A, URB597 and VDM-11, in sleep homeostasis","volume":"339","author":"Murillo-Rodr\u00edguez","year":"2016","journal-title":"Neuroscience"},{"issue":"January","key":"10.1016\/j.neuro.2019.08.002_bib0765","article-title":"Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice","author":"Myers","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuro.2019.08.002_bib0770","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/fcp.12051","article-title":"Cannabidiol reverses the mCPP-induced increase in marble-burying behaviour","volume":"28","author":"Nardo","year":"2014","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.neuro.2019.08.002_bib0775","series-title":"The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research","author":"National Academies of Sciences, Engineering, and Medicine","year":"2017"},{"issue":"3","key":"10.1016\/j.neuro.2019.08.002_bib0780","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/01.jcp.0000125688.05091.8f","article-title":"Effect of D-9-Tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults","volume":"24","author":"Nicholson","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0785","doi-asserted-by":"crossref","first-page":"29","DOI":"10.9740\/mhc.2017.01.029","article-title":"Evidence for the use of \"medical marijuana\" in psychiatric and neurologic disorders","volume":"7","author":"Noel","year":"2018","journal-title":"Ment Health Clin."},{"issue":"Supp 1","key":"10.1016\/j.neuro.2019.08.002_bib0790","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1093\/schbul\/sby018.939","article-title":"Cannabidiol induced modulation of mediotemporal activity during a verbal memory task in first-episode psychosis","volume":"44","author":"O\u2019Neill","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuro.2019.08.002_bib0795","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.neubiorev.2016.11.012","article-title":"A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia","volume":"72","author":"Osborne","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"April (6)","key":"10.1016\/j.neuro.2019.08.002_bib0800","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11920-019-1026-z","article-title":"Cannabinoid regulation of fear and anxiety: an update","volume":"21","author":"Papagianni","year":"2019","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.neuro.2019.08.002_bib0805","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00213-004-1825-7","article-title":"Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats","volume":"175","author":"Parker","year":"2004","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0810","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.expneurol.2010.03.018","article-title":"The endocannabinoid system and psychiatric disorders","volume":"224","author":"Parolaro","year":"2010","journal-title":"Exp. Neurol."},{"issue":"1\u20133","key":"10.1016\/j.neuro.2019.08.002_bib0815","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.schres.2016.01.056","article-title":"Cannabis-induced psychosis associated with high potency \u201cwax dabs\u201d","volume":"172","author":"Pierre","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuro.2019.08.002_bib0820","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2017.02.041","article-title":"Cannabidiol: state of the art and new challenges for therapeutic applications","volume":"175","author":"Pisanti","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.neuro.2019.08.002_bib0825","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/cpt1972133426","article-title":"Delta-9-tetrahydrocannabinol and synhexl: effects on human sleep patterns","volume":"13","author":"Pivik","year":"1972","journal-title":"Clin. Pharmacol. Ther."},{"issue":"March","key":"10.1016\/j.neuro.2019.08.002_bib0830","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pnpbp.2018.08.030","article-title":"Cannabidiol as a suggested candidate for treatment of autism spectrum disorder","volume":"89","author":"Poleg","year":"2019","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.neuro.2019.08.002_bib0835","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/0269881107083816","article-title":"Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy","volume":"22","author":"Potvin","year":"2008","journal-title":"J. Psychopharmacol. (Oxford)"},{"key":"10.1016\/j.neuro.2019.08.002_bib0840","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.lfs.2019.03.053","article-title":"Cannabidiol: recent advances and new insights for neuropsychiatric disorders treatment","volume":"224","author":"Premoli","year":"2019","journal-title":"Life Sci."},{"issue":"February","key":"10.1016\/j.neuro.2019.08.002_bib0845","article-title":"Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder","author":"Pretzsch","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuro.2019.08.002_bib0850","first-page":"33","article-title":"Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence","volume":"9","author":"Prud\u2019homme","year":"2015","journal-title":"Subst. Abuse"},{"issue":"Suppl 1","key":"10.1016\/j.neuro.2019.08.002_bib0855","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1093\/schbul\/sby014.066","article-title":"Efficacy of cannabidiol in the treatment of early psychosis","volume":"44","author":"Ranganathan","year":"2018","journal-title":"Schizoph Bull."},{"issue":"November (47)","key":"10.1016\/j.neuro.2019.08.002_bib0860","doi-asserted-by":"crossref","first-page":"14764","DOI":"10.1523\/JNEUROSCI.4291-09.2009","article-title":"Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances","volume":"29","author":"Ren","year":"2009","journal-title":"J. Neurosci."},{"issue":"7","key":"10.1016\/j.neuro.2019.08.002_bib0865","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.1476-5381.2008.00107.x","article-title":"Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice","volume":"156","author":"Riedel","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"34","key":"10.1016\/j.neuro.2019.08.002_bib0870","doi-asserted-by":"crossref","first-page":"55840","DOI":"10.18632\/oncotarget.10095","article-title":"Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction","volume":"7","author":"Rodr\u00edguez-Mu\u00f1oz","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.neuro.2019.08.002_bib0875","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3389\/fphar.2016.00422","article-title":"Cannabidiol as a potential new type of an antipsychotic. A critical review of the evidence","volume":"7","author":"Rohleder","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuro.2019.08.002_bib0880","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.phrs.2017.05.005","article-title":"Cannabidiol in medical marijuana: research vistas and potential opportunities","volume":"121","author":"Rong","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuro.2019.08.002_bib0885","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1038\/sj.npp.1301664","article-title":"Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates","volume":"33","author":"Rubino","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuro.2019.08.002_bib0890","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s12640-009-9031-3","article-title":"The depressive phenotype induced in adult female rats by adolescent exposure to THC is associated with cognitive impairment and altered neuroplasticity in the prefrontal cortex","volume":"15","author":"Alberio","year":"2009","journal-title":"Neurotox. Res."},{"issue":"8","key":"10.1016\/j.neuro.2019.08.002_bib0895","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/cbdv.200790150","article-title":"Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine","volume":"4","author":"Russo","year":"2007","journal-title":"Chem. Biodivers."},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0900","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/can.2016.0009","article-title":"Clinical endocannabinoid deficiency reconsidered: current research supports the theory in Migraine, Fibromyalgia, Irritable Bowel and other treatment-resistant syndromes","volume":"1","author":"Russo","year":"2016","journal-title":"Cannabis Cannabinoid Res."},{"issue":"4","key":"10.1016\/j.neuro.2019.08.002_bib0905","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13311-015-0380-8","article-title":"Safety and toxicology of cannabinoids","volume":"12","author":"Sachs","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuro.2019.08.002_bib0910","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bbr.2016.01.033","article-title":"Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-Possible involvement of 5-HT1A and CB1 receptors","volume":"303","author":"Sartim","year":"2016","journal-title":"Behav. Brain Res."},{"issue":"4","key":"10.1016\/j.neuro.2019.08.002_bib0915","doi-asserted-by":"crossref","DOI":"10.3390\/medicines5040107","article-title":"New perspectives on the use of Cannabis in the treatment of psychiatric disorders","volume":"5","author":"Scherma","year":"2018","journal-title":"Medicines"},{"issue":"4","key":"10.1016\/j.neuro.2019.08.002_bib0920","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s12640-014-9457-0","article-title":"Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice","volume":"26","author":"Schiavon","year":"2014","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuro.2019.08.002_bib0925","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pnpbp.2015.06.017","article-title":"Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice","volume":"64","author":"Schiavon","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.neuro.2019.08.002_bib0930","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/17512433.2016.1178571","article-title":"The consequences of drug misuse on post-marketing surveillance","volume":"9","author":"Schifano","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuro.2019.08.002_bib0935","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0269881117735684","article-title":"Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: a case series","volume":"32","author":"Schipper","year":"2018","journal-title":"J. Psychopharmacol. (Oxford)"},{"issue":"3","key":"10.1016\/j.neuro.2019.08.002_bib0940","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/hup.1196","article-title":"A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use","volume":"26","author":"Schoedel","year":"2011","journal-title":"Hum. Psychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.neuro.2019.08.002_bib0945","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.schres.2011.04.017","article-title":"Cannabis with high cannabidiol content is associated with fewer psychotic experiences","volume":"130","author":"Schubart","year":"2011","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.neuro.2019.08.002_bib0950","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ptr.2625","article-title":"Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders","volume":"23","author":"Scuderi","year":"2009","journal-title":"Phytother. Res."},{"issue":"10","key":"10.1016\/j.neuro.2019.08.002_bib0955","doi-asserted-by":"crossref","first-page":"e920","DOI":"10.1038\/tp.2016.195","article-title":"Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose","volume":"6","author":"Seeman","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuro.2019.08.002_bib0960","doi-asserted-by":"crossref","first-page":"108","DOI":"10.7812\/TPP\/16-005","article-title":"Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report","volume":"20","author":"Shannon","year":"2016","journal-title":"Perm. J."},{"key":"10.1016\/j.neuro.2019.08.002_bib0965","first-page":"23","article-title":"Cannabidiol in anxiety and sleep: a large case series","author":"Shannon","year":"2019","journal-title":"Perm. J."},{"issue":"3(2)","key":"10.1016\/j.neuro.2019.08.002_bib0970","first-page":"123","article-title":"Prohedonic effect of cannabidiol in a rat model of depression","volume":"7","author":"Zalsman","year":"2016","journal-title":"Neuropsychobiology"},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0975","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/can.2017.0043","article-title":"Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular Cannabis users: a pragmatic open-label clinical trial","volume":"3","author":"Solowij","year":"2018","journal-title":"Cannabis Cannabinoid Res."},{"issue":"2","key":"10.1016\/j.neuro.2019.08.002_bib0980","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/1570159X14666160509123955","article-title":"Evidences for the anti-panic actions of cannabidiol","volume":"15","author":"Soares","year":"2017","journal-title":"Curr. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib0985","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00406-019-00978-2","article-title":"A randomised controlled trial of vaporised \u03949-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects","volume":"269","author":"Solowij","year":"2019","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.neuro.2019.08.002_bib0990","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neuroscience.2017.07.018","article-title":"Effects of cannabinoid drugs on aversive or rewarding drug-associated memory extinction and reconsolidation","volume":"370","author":"Stern","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuro.2019.08.002_bib0995","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.neuropharm.2017.07.024","article-title":"Cannabidiol disrupts the consolidation of specific and generalized fear memories via dorsal hippocampus CB1 and CB2 receptors","volume":"125","author":"Stern","year":"2017","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.neuro.2019.08.002_bib1000","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41386-018-0282-7","article-title":"\u0394-9-Tetrahydrocannabinol and Cannabidiol produce dissociable effects on prefrontal cortical executive function and regulation of affective behaviors","volume":"44","author":"Szkudlarek","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.neuro.2019.08.002_bib1005","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0376-8716(96)01277-X","article-title":"A community survey of adverse effects of cannabis use","volume":"42","author":"Thomas","year":"1996","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10.1016\/j.neuro.2019.08.002_bib1010","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuro.2019.08.002_bib1015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.3485","article-title":"Assessment of efficacy and tolerability of medicinal cannabinoids in patients with multiple sclerosis: a systematic review and meta-analysis","volume":"1","author":"Torres-Moreno","year":"2018","journal-title":"JAMA Netw Open."},{"key":"10.1016\/j.neuro.2019.08.002_bib1020","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.drugalcdep.2016.02.020","article-title":"Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings","volume":"161","author":"Trigo","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuro.2019.08.002_bib1025","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.drugalcdep.2016.02.020","article-title":"Effects of fixed or self-titrated dosages of Sativex on cannabis users","volume":"161","author":"Trigo","year":"2016","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib1030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190768","article-title":"Nabiximols combined with motivational enhancement\/cognitive behavioural therapy for the treatment of cannabis dependence: a pilot randomized clinical trial","volume":"13","author":"Trigo","year":"2018","journal-title":"PLoS One"},{"issue":"January","key":"10.1016\/j.neuro.2019.08.002_bib1035","article-title":"Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: a systematic review","author":"Turna","year":"2019","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.neuro.2019.08.002_bib1040","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.nlm.2018.02.009","article-title":"Learning and memory is modulated by cannabidiol when administered during trace fear-conditioning","volume":"149","author":"Uhernik","year":"2018","journal-title":"Neurobiol. Learn. Mem."},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib1045","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12888-019-2022-x","article-title":"Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial","volume":"19","author":"van der Flier","year":"2019","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.neuro.2019.08.002_bib1050","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.drugalcdep.2007.11.017","article-title":"Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol","volume":"94","author":"Vann","year":"2008","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10.1016\/j.neuro.2019.08.002_bib1055","doi-asserted-by":"crossref","DOI":"10.3390\/medicines5030075","article-title":"Effectiveness of raw, natural medical Cannabis flower for treating insomnia under naturalistic conditions","volume":"5","author":"Vigil","year":"2018","journal-title":"Medicines"},{"issue":"8","key":"10.1016\/j.neuro.2019.08.002_bib1060","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.3390\/ph3082689","article-title":"Cannabinoids and dementia: a review of clinical and preclinical data","volume":"3","author":"Walther","year":"2010","journal-title":"Pharmaceuticals"},{"issue":"Supp A","key":"10.1016\/j.neuro.2019.08.002_bib1065","first-page":"31A","article-title":"Safety issues concerning the medical use of cannabis and cannabinoids","volume":"10","author":"Ware","year":"2005","journal-title":"Pain Res. Manag."},{"issue":"3","key":"10.1016\/j.neuro.2019.08.002_bib1070","first-page":"173","article-title":"Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome","volume":"2","author":"Waterlow","year":"2008","journal-title":"Core Evid."},{"issue":"July (7)","key":"10.1016\/j.neuro.2019.08.002_bib1075","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/jcph.1387","article-title":"A review of human studies assessing cannabidiol\u2019s (CBD) therapeutic actions and potential","volume":"59","author":"White","year":"2019","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuro.2019.08.002_bib1080","first-page":"487","article-title":"The effects of leptin in combination with a cannabinoid receptor 1 antagonist, AM 251, or cannabidiol on food intake and body weight in rats fed a high-fat or a free-choice high sugar diet","volume":"65","author":"Wierucka-Rybak","year":"2014","journal-title":"J. Physiol. Pharmacol."},{"issue":"24","key":"10.1016\/j.neuro.2019.08.002_bib1085","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use. A systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.neuro.2019.08.002_bib1090","series-title":"The Health and Social Effects of Nonmedical Cannabis Use","author":"World Health Organisation","year":"2018"},{"issue":"7","key":"10.1016\/j.neuro.2019.08.002_bib1095","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/bph.12199","article-title":"Cannabidiol attenuates deficits of visuospatial associative memory induced by \u0394(9) tetrahydrocannabinol","volume":"170","author":"Wright","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuro.2019.08.002_bib1100","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.neurobiolaging.2012.06.011","article-title":"Activation of the CB(2) receptor system reverses amyloid- induced memory deficiency","volume":"34","author":"Wu","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuro.2019.08.002_bib1105","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nn.2874","article-title":"Brain cannabinoid CB(2) receptors modulate cocaine\u2019s actions in mice","volume":"14","author":"Xi","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuro.2019.08.002_bib1110","doi-asserted-by":"crossref","first-page":"e710","DOI":"10.1038\/tp.2015.201","article-title":"Hippocampal harms, protection and recovery following regular cannabis use","volume":"6","author":"Y\u00fccel","year":"2016","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib1115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1476-5381.2009.00521.x","article-title":"Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors","volume":"159","author":"Zanelati","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuro.2019.08.002_bib1120","doi-asserted-by":"crossref","first-page":"E5007","DOI":"10.1073\/pnas.1413210111","article-title":"Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine- related behavior in mice","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.neuro.2019.08.002_bib1125","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3390\/ph5050529","article-title":"Cannabidiol in humans\u2014the quest for therapeutic targets","volume":"5","author":"Zhornitsky","year":"2012","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.neuro.2019.08.002_bib1130","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF00432554","article-title":"Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects","volume":"76","author":"Zuardi","year":"1982","journal-title":"Psychopharmacology"},{"issue":"Supp 1","key":"10.1016\/j.neuro.2019.08.002_bib1135","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/026988119300700112","article-title":"Effects of ipsapirone and cannabidiol on human experimental anxiety","volume":"7","author":"Zuardi","year":"1993","journal-title":"J. Psychopharmacol. (Oxford)"},{"issue":"10","key":"10.1016\/j.neuro.2019.08.002_bib1140","first-page":"485","article-title":"Antipsychotic effect of cannabidiol","volume":"56","author":"Zuardi","year":"1995","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.neuro.2019.08.002_bib1145","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1590\/S0100-879X2006000400001","article-title":"Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug","volume":"39","author":"Zuardi","year":"2006","journal-title":"Br. J. Med. Biol. Res."},{"issue":"5","key":"10.1016\/j.neuro.2019.08.002_bib1150","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1177\/0269881106060967","article-title":"Cannabidiol monotherapy for treatment-resistant schizophrenia","volume":"20","author":"Zuardi","year":"2006","journal-title":"J. Psychopharmacol. (Oxford)"},{"issue":"3","key":"10.1016\/j.neuro.2019.08.002_bib1155","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1590\/S1516-44462008000300015","article-title":"Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action","volume":"30","author":"Zuardi","year":"2008","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.neuro.2019.08.002_bib1160","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/0269881108096521","article-title":"Cannabidiol was ineffective for manic episode of bipolar affective disorder","volume":"24","author":"Zuardi","year":"2010","journal-title":"J. Psychopharmacol. (Oxford)"},{"issue":"32","key":"10.1016\/j.neuro.2019.08.002_bib1165","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.2174\/138161212802884681","article-title":"A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation","volume":"18","author":"Zuardi","year":"2012","journal-title":"Curr. Pharm. Des."}],"container-title":["NeuroToxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161813X19300774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161813X19300774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:23:04Z","timestamp":1758982984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161813X19300774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":233,"alternative-id":["S0161813X19300774"],"URL":"https:\/\/doi.org\/10.1016\/j.neuro.2019.08.002","relation":{},"ISSN":["0161-813X"],"issn-type":[{"value":"0161-813X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabidiol (CBD) use in psychiatric disorders: A systematic review","name":"articletitle","label":"Article Title"},{"value":"NeuroToxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuro.2019.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}